Ballicules.com

Nicotine patch

NICODERM CQ

What it isNicotine transdermal patch (NICODERM CQ, Rx ~1991, OTC 1996) is a neuronal nicotinic receptor agonist for smoking cessation.

Why this oneSteady 16-24 h nicotine delivery provides baseline coverage without reinforcing peaks and works best with gum or lozenge for breakthrough craving.

What limits itSkin irritation and vivid dreams are common; remove at night if dreams or insomnia interfere, and rotate sites.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Smoking cessation aid — reduces withdrawal symptoms/craving (>10 cigarettes/day)Adults21 mg/day (Step 1, weeks 1–6)14 mg/day (Step 2, weeks 7–8)7 mg/day (Step 3, weeks 9–10) then stop
Smoking cessation aid — reduces withdrawal symptoms/craving (≤10 cigarettes/day)Adults14 mg/day (Step 2, 6 weeks)7 mg/day (Step 3, 2 weeks)7 mg/day then stop

Renal Undefined

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy If pregnant, use only on the advice of a healthcare provider; try to stop smoking without nicotine replacement

Lactation If breast-feeding, use only on the advice of a healthcare provider

NO BOXED WARNINGS

Principal riskLocal irritation; vivid dreams with the overnight patch

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Nicotine patch ballicule

Nicotine patch ballicule: receptor binding, kinetics and half-life diagram

Open Nicotine patch in the interactive console ↗

Memory aids: mascots and interaction avatars

Nicotine patch NICODERM CQ mascot mnemonic cartoon
Nicotine patch mnemonic
Nicotine patch Box: minimal PK interactions avatar
Box: minimal PK interactions

Open Nicotine patch in the interactive console ↗